Kristine Cooper

Kristine Cooper

Auto-generated profile, based on publicly available information

Kristine Cooper

UPMC Hillman Cancer Center Biostatistics Facility, Pittsburgh, Pennsylvania

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
NTNaveen Kumar Tangudu
Naveen Kumar Tangudu
RBRaquel Buj
Raquel Buj
HWHui Wang
Hui Wang
JWJiefei Wang
Jiefei Wang
ACAidan R. Cole
Aidan R. Cole
KAKatherine Aird
Katherine Aird
P16 is a tumor suppressor encoded by the CDKN2A gene whose expression is lost in approximately 50% of all human cancers. In its canonical role, p16 inhibits the G1–S-phase cell cycle progression through suppression of cyclin-dependent kinases. Interestingly, p16 also has roles in metabolic reprogramming, and we previously published that loss of p16 promotes nucleotide synthesis via the pentose phosphate pathway. However, the broader impact of p16/CDKN2A loss on other nucleotide metabolic pathways and potential therapeutic targets remains unexplored. Using CRISPR knockout libraries in isogenic human and mouse melanoma cell lines, we determined several nucleotide metabolism genes essential for the survival of cells with loss of p16/CDKN2A. Consistently, many of these genes are upregulated in melanoma cells with p16 knockdown or endogenously low CDKN2A expression. We determined that cells with low p16/CDKN2A expression are sensitive to multiple inhibitors of de novo purine synthesis, including antifolates. Finally, tumors with p16 knockdown were more sensitive to the antifolate methotrexate in vivo than control tumors. Together, our data provide evidence to reevaluate the utility of these drugs in patients with p16/CDKN2Alow tumors as loss of p16/CDKN2A may provide a therapeutic window for these agents. Significance: Antimetabolites were the first chemotherapies, yet many have failed in the clinic due to toxicity and poor patient selection. Our data suggest that p16 loss provides a therapeutic window to kill cancer cells with widely-used antifolates with relatively little toxicity.

11 February 2022 in Journal of Genetic Counseling
Verified
Journal Article
Closed access
PDF file
RVRosemarie E. Venier
Rosemarie E. Venier
RGRobin E. Grubs
Robin E. Grubs
EKElena Kessler
Elena Kessler
KCKristine L. Cooper
Kristine L. Cooper
KBKelly M. Bailey
Kelly M. Bailey
JMJulia Meade
Julia Meade

1 August 2025 in Cancer Research Communications
Verified
Journal Article
Open access
JDJessica D. Daley
Jessica D. Daley
EMElina Mukherjee
Elina Mukherjee
DFDavid Ferraro
David Ferraro
ATA. Carolina Tufino
A. Carolina Tufino
NBNathanael Glen Bailey
Nathanael Glen Bailey
KBKelly M. Bailey
Kelly M. Bailey
Ewing sarcoma is an aggressive cancer diagnosed in adolescents and young adults. Inhibition of TGFβ is being tested in limited clinical trials for relapsed Ewing sarcoma. TGFβ is an immunosuppressive cytokine that exists in latent and active states. The functional impact of TGFβ inhibition on the Ewing tumor microenvironment (TME) and on Ewing tumor behavior remains largely unknown. In this study, we use single-cell RNA sequencing analysis of human Ewing tumors to demonstrate that immune cells are the largest contributors of TGFB1 expression in the human Ewing TME. We utilize a humanized mouse model of Ewing sarcoma to demonstrate that TME signatures in these models differ significantly from Ewing sarcoma tumors developed in immunodeficient mice. Using this humanized model, we investigate the effect of TGFβ inhibition on the Ewing sarcoma TME during radiotherapy, a treatment that is commonly used to treat unresectable, metastatic, and relapsed/refractory Ewing sarcoma that is known to enhance TGFβ activation in multiple cancers. Utilizing a trivalent ligand TGFβ trap to inhibit TGFβ, we demonstrate that in combination with radiotherapy, TGFβ inhibition both increases Ewing sarcoma immune cell infiltration and decreases lung metastatic burden in vivo. These data demonstrate the value of immunocompetent models to address immune-biological preclinical questions in Ewing sarcoma and demonstrate that TGFβ inhibition during radiotherapy is a promising strategy to enhance antitumor immune response and improve treatment efficacy for metastatic Ewing sarcoma. Significance: This work demonstrates the importance of disrupting immunosuppression during radiotherapy to reduce lung metastatic potential in Ewing sarcoma. Humanized mouse models of Ewing sarcoma are also established as an immunocompetent preclinical tool to ask therapeutic questions about the Ewing TME.

20 December 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
LCLauren Cowen
Lauren Cowen
PNPrachi Namjoshi
Prachi Namjoshi
GGGabriela Giordano
Gabriela Giordano
SKSudeep Kumar
Sudeep Kumar
JBJennifer D. Bowling
Jennifer D. Bowling
Karsten HazlettKarsten Hazlett
Karsten Hazlett
Identifying correlates of protection (COPs) for vaccines against lethal human (Hu) pathogens, such as Francisella tularensis (Ft), is problematic, as clinical trials are currently untenable and the relevance of various animal models can be controversial. Previously, Hu trials with the live vaccine strain (LVS) demonstrated ~80% vaccine efficacy against low dose (~50 CFU) challenge; however, protection deteriorated with higher challenge doses (~2000 CFU of SchuS4) and no COPs were established. Here, we describe our efforts to develop clinically relevant, humoral COPs applicable to high-dose, aerosol challenge with S4. First, our serosurvey of LVS-vaccinated Hu and animals revealed that rabbits (Rbs), but not rodents, recapitulate the Hu O-Ag dependent Ab response to Ft. Next, we assayed Rbs immunized with distinct S4-based vaccine candidates (S4ΔclpB, S4ΔguaBA, and S4ΔaroD) and found that, across multiple vaccines, the %O-Ag dep Ab trended with vaccine efficacy. Among S4ΔguaBA-vaccinated Rbs, the %O-Ag dep Ab in pre-challenge plasma was significantly higher in survivors than in non-survivors; a cut-off of >70% O-Ag dep Ab predicted survival with high sensitivity and specificity. Finally, we found this COP in 80% of LVS-vaccinated Hu plasma samples as expected for a vaccine with 80% Hu efficacy. Collectively, the %O-Ag dep Ab response is a bona fide COP for S4ΔguaBA-vaccinated Rb and holds significant promise for guiding vaccine trials with higher animals.

16 March 2023 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
KDKristen R. Msgc D’aquila
Kristen R. Msgc D’aquila
EKElena Msgc Kessler
Elena Msgc Kessler
KCKristine L. Cooper
Kristine L. Cooper
ADAndrea L Durst
Andrea L Durst
JMJulia Meade
Julia Meade
Five to 10% of children with cancer are thought to have a cancer predisposition syndrome (CPS). Referral guidelines for leukemia predisposition syndromes are limited and vague, requiring the treating provider to determine whether patients should have a genetics evaluation. We evaluated referrals to the pediatric cancer predisposition clinic (CPP), the prevalence of CPS in those who elected to pursue germline genetic testing, and assessed for associations between a patient’s medical history and the diagnosis of a CPS. Data were obtained via chart review of children diagnosed with leukemia or myelodysplastic syndrome between November 1, 2017, and November 30, 2021. A total of 22.7% of pediatric leukemia patients were referred for evaluation in the CPP. Of the participants evaluated with germline genetic testing, the prevalence of a CPS was 25%. Our study was able to find a CPS in different malignancies, including acute lymphoblastic leukemia, acute myeloid leukemia, and myelodysplastic syndrome. We did not find associations between a participant with an abnormal CBC before diagnosis or hematology visit and the diagnosis of a CPS. Our study supports that a genetic evaluation should be available to all children with leukemia as medical and family history alone is not predictors of a CPS.

26 June 2025 in Journal of Genetic Counseling
Verified
Journal Article
Open access
EWElise G. Williams
Elise G. Williams
EKElena Kessler
Elena Kessler
KCKristine L. Cooper
Kristine L. Cooper
ADAndrea L Durst
Andrea L Durst
JMJulia Meade
Julia Meade
The multi‐gene panel is the most utilized genetic test to evaluate for germline cancer predisposition syndromes. However, the rate of change of commercial multigene panels is not well understood, and its value as a standalone test has also not been investigated. We conducted a retrospective chart review of the UPMC Children's Hospital of Pittsburgh Cancer Predisposition Program's genetic testing results to evaluate how multigene panels for pediatric and young adult patients with cancer have changed in size and scope from 2018 to 2022. We find that multigene panels show a trend of growing larger in number of genes included over time and explore the utility of additional genetic testing after the initial round of multi‐gene panel testing. We demonstrate heterogeneity between commercial genetic testing laboratories and their panels over time, signifying a need for equity among genetic testing panels and vigilance among physicians and genetic counselors ordering panel‐based testing.